Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 5:16 pm Purchase | 2024-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | Kynam Capital Management LP | 5,064,207 7.630% | 2,058,303 (+68.48%) | Filing History |
| 2025-02-14 09:44 am Purchase | 2024-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | T. Rowe Price Associates, Inc. | 3,557,136 5.400% | 3,557,136 (New Position) | Filing History |
| 2025-02-12 09:28 am Sale | 2024-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | FMR LLC | 4,857,668 7.300% | -1,166,748 (-19.37%) | Filing History |
| 2025-02-05 1:23 pm Purchase | 2024-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | BlackRock Inc. BLK | 5,480,670 8.300% | 1,804,978 (+49.11%) | Filing History |
| 2024-11-14 7:47 pm Sale | 2024-09-30 | 13G | Celldex Therapeutics, Inc. CLDX | Point72 Asset Management, L.P. | 1,684,032 2.500% | -1,072,090 (-38.90%) | Filing History |
| 2024-11-14 12:18 pm Sale | 2024-09-30 | 13G | Celldex Therapeutics, Inc. CLDX | EVENTIDE ASSET MANAGEMENT LLC | 3,332,005 5.030% | -298,008 (-8.21%) | Filing History |
| 2024-11-14 06:12 am Sale | 2024-09-30 | 13G | Celldex Therapeutics, Inc. CLDX | RTW INVESTMENTS LP | 0 0.000% | -3,463,201 (Position Closed) | Filing History |
| 2024-11-13 6:00 pm Sale | 2024-09-30 | 13G | Celldex Therapeutics, Inc. CLDX | Polar Capital Holdings Plc | 2,711,163 4.090% | -424,708 (-13.54%) | Filing History |
| 2024-11-12 09:55 am Sale | 2024-11-08 | 13G | Celldex Therapeutics, Inc. CLDX | FMR LLC | 6,024,416 9.088% | -1,025,993 (-14.55%) | Filing History |
| 2024-11-08 10:52 am Purchase | 2024-09-30 | 13G | Celldex Therapeutics, Inc. CLDX | Wellington Management Group LLP | 9,243,599 13.940% | 2,767,038 (+42.72%) | Filing History |
| 2024-02-14 4:17 pm Sale | 2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | Point72 Asset Management, L.P. | 2,756,122 5.000% | -866,014 (-23.91%) | Filing History |
| 2024-02-14 12:52 pm Purchase | 2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | Kynam Capital Management LP | 3,005,904 5.500% | 3,005,904 (New Position) | Filing History |
| 2024-02-14 11:48 am Purchase | 2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | EVENTIDE ASSET MANAGEMENT LLC | 3,630,013 6.640% | 3,630,013 (New Position) | Filing History |
| 2024-02-14 07:38 am Purchase | 2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | RTW INVESTMENTS LP | 3,463,201 6.300% | 378,986 (+12.29%) | Filing History |
| 2024-02-13 5:00 pm Purchase | 2023-12-29 | 13G | Celldex Therapeutics, Inc. CLDX | VANGUARD GROUP INC | 3,046,331 5.570% | 532,767 (+21.20%) | Filing History |
| 2024-02-13 09:41 am Purchase | 2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | Polar Capital Holdings Plc | 3,135,871 5.730% | 3,135,871 (New Position) | Filing History |
| 2024-02-09 08:50 am Sale | 2024-02-08 | 13G | Celldex Therapeutics, Inc. CLDX | FMR LLC | 7,050,409 12.891% | -14,565 (-0.21%) | Filing History |
| 2024-02-08 10:11 am Purchase | 2023-12-29 | 13G | Celldex Therapeutics, Inc. CLDX | Wellington Management Group LLP | 6,476,561 11.840% | 1,695,064 (+35.45%) | Filing History |
| 2024-01-26 5:25 pm Purchase | 2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | BlackRock Inc. BLK | 3,675,692 6.700% | 450,976 (+13.98%) | Filing History |
| 2023-11-20 4:15 pm Purchase | 2023-11-10 | 13G | Celldex Therapeutics, Inc. CLDX | Point72 Asset Management, L.P. | 3,622,136 6.600% | 3,622,136 (New Position) | Filing History |